bioRxiv · 10.1101/2023.02.20.529249
Antibody-mediated cell entry of SARS-CoV-2
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by first engaging its cellular receptor angiotensin converting enzyme 2 (ACE2) to induce conformational changes in the virus-encoded spike protein and fusion between the viral and target cell membranes. We report here that certain monoclonal neutralizing antibodies against distinct epitopic regions of the receptor-binding domain of the spike can replace ACE2 to serve as a receptor and efficiently support membrane fusion and viral infectivity. These receptor-like antibodies can function in the form of a complex of their soluble immunoglobulin G with Fc-gamma receptor I, a chimera of their antigen-binding fragment with the transmembrane domain of ACE2 or a membrane-bound B cell receptor, indicating that ACE2 and its specific interactions with the spike protein are dispensable for SARS-CoV-2 entry. These results suggest that antibody responses against SARS-CoV-2 may expand the viral tropism to otherwise nonpermissive cell types; they have important implications for viral transmission and pathogenesis.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Kibria, M. G., Lavine, C. L., Tang, W., Wang, S., Gao, H., Shi, W., Zhu, H., Voyer, J., Rits-Volloch, S., Keerti, F., Bi, C., Peng, H., Wesemann, D., Lu, J., Xie, H., Seaman, M. S., Chen, B.. 2023-02-20. Antibody-mediated cell entry of SARS-CoV-2. https://doi.org/10.1101/2023.02.20.529249
Cite the original work for its findings. Save a collection to share your selection of sources.